紫杉醇联合顺铂方案治疗晚期非小细胞肺癌临床观察  

Clinical Effect of Combination of Paclitaxel and Cisplatin in the Treatment of Patients with Advanced Non-small-cell Lung Cancer

作　　者：代云峰[1] 周政[1] 

机构地区：[1]安徽省寿县人民医院内科,232200

出　　处：《中华全科医学》2009年第10期1077-1078,共2页Chinese Journal of General Practice

摘　　要：目的观察紫杉醇联合顺铂方案(TP方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法63例中晚期NSCLC患者均采用TP方案化疗,观察有效率、中位生存期、1年生存率及毒副作用。结果63例患者总有效率为49.2%(31/63),初治组和复治组的有效率分别为57.1%(24/42)和33.3%(7/21),两组比较差异无统计学意义(χ2=3.7154,P=0.0748),中位生存期(12.00±0.64)月,1年生存率为31.1%;常见的毒副作用为骨髓抑制及消化道反应,但均在可耐受的范围内。结论TP方案治疗晚期非小细胞肺癌能取得较好的疗效,患者耐受性较好。Objective To evaluate the efficacy and toxicities of the combination of paclitaxel plus cisplatin（TP） in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods 63 patients with advanced NSCLC were accepted the protocol of TP. Therapeutic effect and side-effects were observed. Results In 63 patients,the overall response rate was 49.2%. Response rates of initial treatment and retreatment were 57. 1% （24/42） and 33.3% （7/21） respectively. No significant difference was seen between two groups （χ^2 = 3. 7154,P =0. 0748 ）. Median survival time （MST） was 12.0 ± 0.6 months. 1 year survival rate was 31.1%. The main toxicities were hypoplasia of bone marrow and digestive system reaction, all of these can be tolerated by patients. Conclusion The combination therapy of paclitaxel plus cisplatin could be the ideal chemotherapy protocol for patients with advanced NSCLC.

关 键 词：紫杉醇 顺铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]